COYO-GMBH
20.7.2021 16:28:52 CEST | Business Wire | Press release
COYO, the leading social intranet and employee communications platform, lands a coup with the acquisition of Paris-based people analytics platform Jubiwee. For the past 5 years Jubiwee has been doubling its operations and customer-base yearly. Over 40 French blue-chip companies use Jubiwee to assess staff motivation or to support transformation projects. In joining forces with Jubiwee, COYO accelerates its internationalization outside the DACH region and adds a critical toolkit to its digital workplace proposition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005881/en/
Since the virus fast-tracked remote work, countless businesses have learned that their operational effectiveness in remote scenarios was heavily dependent on employee engagement. With Jubiwee's engagement analytics tools and their own communications and intranet platform, COYO now brings a complete employee engagement offering to the market. Customers will be enabled to address the limitations of remote work and make it more successful for employers and employees alike.
To ensure continuity and stability both company- and product-wise, Thibaud Martin, co-founder of Jubiwee, will join the COYO management team. Jubiwee’s office in Paris will become COYO’s French head office. Jubiwee customers have already been informed that their product of choice will be continued and even enhanced.
With the ambition to build ‘sexy and engaging business software’, Hamburg-based tech entrepreneur Jan Marius Marquardt founded COYO in 2010. The current platform is a modern social intranet and employee app that empowers organizations to drive employee engagement and improve workplace culture. The platform has over 400 customers, serving more than 1 million end-users. Jan Marius Marquardt, founder and CEO of COYO, says: “I am beyond happy about joining forces with Jubiwee: It feels like the right step, pushing the company and product to the next level and accelerate our expansion to France, one of our priority markets. Beyond cool technology there is no better way to start building up a French presence than by teaming up with a French team that has already proven successful and shares our values. This addition is a next big step towards becoming the most widely adopted employee communications platform in the world.”
Both companies have European DNA, share the same culture and vision and are very product-focused: UX and UI are critical, while user adoption is above-market. Jubiwee’s tech and UX-centered product resonates strongly with COYO’s product philosophy. Jan Marius Marquardt explains: “A capable engagement analytics solution is instrumental in a truly 360° employee communications offering and will bring a lot of value to customers. The merger thus presents an excellent opportunity for both current German and French customers.”
Jubiwee was founded in 2016 by Thibaud Martin, Victor Mustar, and Antoine Bellion. The company offers a new generation engagement analytics platform with a user-centric approach to improve employee experience, reduce turnover and improve retention. Thibaud Martin, co-founder, and CEO of Jubiwee, explains: “The people analytics and overall employee engagement market has grown tremendously in recent months, partly due to the COVID-crisis. Also, customers have grown more mature and demanding. To capitalize on this shift, we decided to partner with a strong, renowned, and ambitious company that shares the same values: COYO. Joining forces with COYO is the best way to build a more comprehensive offer and accelerate at this crucial time.”
Both solutions will be continued in their current form and developed according to their respective roadmaps. Short-term ambitions include continuing Jubiwee’s growth in France, cross-selling respective solutions to existing customers and prospects as well as introducing the COYO offer in France. Mid and long-term ambitions include integrating both solutions to offer a complete employee engagement suite, enabling companies to communicate, and take the pulse of their coworkers in a modern, efficient and seamless way. Overall, the companies’ solutions are complementary and together present a strong offering, both in terms of depth and breadth. By adding two very competent best-of-breed solutions, COYO and Jubiwee are creating one extremely compelling suite.
More information is available at www.coyoapp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005881/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
